Molecular Partners AG (NASDAQ:MOLN – Get Rating) was the recipient of a significant growth in short interest in the month of March. As of March 31st, there was short interest totalling 20,600 shares,  a growth of 32.1% from the March 15th total of 15,600 shares. Based on an average daily volume of 2,200 shares, the short-interest ratio is presently 9.4 days.

Institutional investors and hedge funds have recently modified their holdings of the business. Tang Capital Management LLC purchased a new stake in shares of  Molecular Partners in the third quarter valued at about $105,000.  AlphaCentric Advisors LLC purchased a new stake in shares of  Molecular Partners in the third quarter valued at about $218,000.  Federated Hermes Inc. lifted its holdings in shares of  Molecular Partners by 94.2% in the first quarter. Federated Hermes Inc. now owns 457,037 shares of the company’s stock valued at $9,264,000 after purchasing an additional 221,743 shares in the last quarter.  Susquehanna International Group LLP purchased a new stake in shares of  Molecular Partners in the fourth quarter valued at about $218,000.  Finally, OLD Mission Capital LLC purchased a new stake in shares of  Molecular Partners in the fourth quarter valued at about $30,000. Hedge funds and other institutional investors own  2.56% of the company’s stock.

Shares of NASDAQ MOLN traded up $0.33 during midday trading on Wednesday, hitting $6.23. The company had a trading volume of 1,592 shares, compared to its average volume of 2,183. The business has a 50-day simple moving average of $6.19 and a two-hundred day simple moving average of $6.44. Molecular Partners has a twelve month low of $5.50 and a twelve month high of $18.40.

Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus.

Receive News & Ratings for Molecular Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Molecular Partners and related companies with MarketBeat.com's FREE daily email newsletter.